Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 447,278 shares at an average price of $1.54, totaling approximately $688,808.
• The company's shares are scheduled for a 1-20 reverse split on September 19th, 2023, affecting the number of shares owned by shareholders.
• Vor Biopharma's current stock performance shows a market cap of $192.56 million, with a one-year trading range from $0.13 to $3.29.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the transaction, the insider owned 32,781,209 shares of the company's stock, valued at approximately $50,483,061.86. This trade represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, September 15th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.64, for a total value of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.75, for a total value of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 284,805 shares of Vor Biopharma stock. The stock was sold at an average price of $1.83, for a total value of $521,193.15.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The stock was sold at an average price of $1.99, for a total transaction of $924,197.79.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.82, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.97, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total value of $1,620,765.51.

Vor Biopharma Stock Performance

Vor Biopharma stock remained flat at $1.52 during midday trading on Thursday. The company's stock had a trading volume of 4,730,618 shares, compared to its average volume of 7,578,729. The stock has a market cap of $192.56 million, a P/E ratio of -0.92 and a beta of 2.05. The stock's fifty day moving average is $2.04 and its 200-day moving average is $1.14. Vor Biopharma Inc. has a one year low of $0.13 and a one year high of $3.29.

Shares of Vor Biopharma are scheduled to reverse split before the market opens on Friday, September 19th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, September 18th.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP increased its position in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares during the period. Money Concepts Capital Corp lifted its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after acquiring an additional 26,535 shares during the period. XTX Topco Ltd purchased a new position in shares of Vor Biopharma in the 2nd quarter valued at approximately $66,000. Northern Trust Corp increased its holdings in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after purchasing an additional 44,252 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares during the period. Institutional investors and hedge funds own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.